Latest Adalimumab Stories

ABBOTT PARK, Ill., Oct. 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2012. Diluted earnings per share, excluding specified items, were $1.30, reflecting 10.2 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.21, including specified items. Excluding foreign exchange, worldwide sales increased 4.1 percent. Reported...

ABBOTT PARK, Ill., Sept. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary...

Tokyo, Sept 11, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the anti-rheumatic agent Careram(R) (iguratimod) in Japan on September 12 for the treatment of rheumatoid arthritis. Careram, jointly developed in Japan by Eisai and Toyama Chemical Co., Ltd. from the Phase III clinical development stage, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) in June of this year and was subsequently listed on the National...

Lee Rannals for redOrbit.com – Your Universe Online People suffering from ulcerative colitis may be getting some new relief due to a decision by the Food and Drug Administration (FDA) to expand the use of a new drug to help alleviate symptoms. An FDA panel voted 15 to 2 that the benefits of Humira outweighed the risks it causes when treating the condition. Humira is already approved to be used for six other conditions, and is most popular for its use to help in rheumatoid arthritis...

Study compares overall mortality in TNF inhibitors: Humira, Enbrel, and Remicade New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now...

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes intestinal inflammation, is on the rise in children. This study is the largest double-blind study of...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring test, PROMETHEUS Anser IFX. This test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients using infliximab - helping physicians identify potential causes for loss of treatment response and helping to guide patient...

ABBOTT PARK, Ill., July 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2012. Diluted earnings per share, excluding specified items, were $1.23, reflecting 9.8 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.08, including specified items. Excluding foreign exchange, worldwide sales increased 6.7 percent. Reported...

Safety of treatments was similar with fewer injection site reactions observed with abatacept Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20. The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in...

Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs). Cost savings were mostly on drug costs. The Dutch study, which investigated 272...